$AVR News

Anteris Technologies secures German clearance to expand PARADIGM heart valve trial

Anteris Advances Global PARADIGM Trial Expansion with German Regulatory Clearance

Cantor Fitzgerald Reiterates Overweight on Anteris Technologies Glb, Maintains $15 Price Target

Barclays Initiates Coverage On Anteris Technologies Glb with Equal-Weight Rating, Announces Price Target of $10

Anteris Technologies appoints Brent Moen as chief financial officer

Anteris to Present at September Healthcare Investor Conferences

Cantor Fitzgerald Reiterates Overweight on Anteris Technologies Glb, Maintains $15 Price Target

Reported Earlier, Anteris Technologies Glb Q2 EPS $(0.30) Misses $(0.21) Estimate, Sales $1.009M Miss $1.500M Estimate

Anteris Technologies advances PARADIGM Trial in June quarter as US patient recruitment gets underway

Anteris Technologies Announces Results for the Second Quarter of 2026

TAVR Changed Valve Replacement; Anteris Says Longer-Living Patients Expose the Next Challenge

France clearance marks key milestone for Anteris' pivotal PARADIGM Trial

Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance

Anteris Technologies Receives Full Regulatory Clearance From The French National Agency For Medicines And Health Products Safety For The DurAVR Transcatheter Heart Valve Global Pivotal Trial In Patients With Severe Calcific Aortic Stenosis

Anteris Technologies Global To Offer Up To $250M Of Common Stock Through TD Cowen

Barclays Maintains Overweight on Anteris Technologies Glb, Raises Price Target to $18

Here's Why We're Not Too Worried About Anteris Technologies Global's (ASX:AVR) Cash Burn Situation

Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors

Anteris adds Susan Knight, Stephen Denaro to board as company advances heart valve strategy

Anteris advances PARADIGM trial as Q1 cash burn reflects commercialisation push